Showing Results for: “type 1 diabetes”

SGLT2i Shown as Potential Solution to Help Manage Renal Complications and Improve Glycemic Control for Young Individuals Living with Type 1 Diabetes Today, findings from the ATTEMPT study, showed that a low-dose of SGLT2 inhibitor could safely be given to youth and adolescents with type 1 diabetes to improve kidney function and glycemic management. ATTEMPT is the first of its kind, landmark trial designed to evaluate the effectiveness of SGLT2 inhibitors to optimize diabetes control and prevent early subclinical kidney complications in an at-risk pediatric population with type 1 diabetes. The

Today, the American Diabetes Association (ADA) sent a letter to the Centers for Disease Control and Prevention (CDC) urging them to take immediate steps to update their guidance on the risk people with type 1 diabetes (T1D) face with COVID-19 and acknowledge that people with both T1D and type 2 diabetes (T2D) should be prioritized equally in the rollout of the vaccine. This change is particularly important because more recent clinical evidence demonstrates that COVID-19 severity is more than tripled in individuals with T1D and time-sensitive, as states are now operationalizing vaccine rollouts

The Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial has found dulaglutide, an injectable, glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates superiority in the reduction of cardiovascular events for a broad range of people living with type 2 diabetes (T2D), according to research presented today at a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. The REWIND trial is the first study to include a majority of participants (69%) with no history of cardiovascular disease (CVD) at enrollment. Additionally, the

Analysis of large international DAPA-HF trial participants notes diabetes prevention benefit in patients with heart failure who took 10 mg of medication The SGLT2 inhibitor dapagliflozin, when used in patients with heart failure, provided a benefit in preventing type 2 diabetes (T2D), according to the study, “Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF,” presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. The original DAPA-HF trial was a phase 3 placebo-controlled international study of

Reduced hospitalization rates among people with low self-monitoring of blood glucose (SMBG) are especially pronounced People using Abbott’s FreeStyle Libre, a sensor-based glucose monitoring system, experienced a considerable decrease in ketoacidosis-related hospitalizations—52% for type 1 diabetes and 47% for type 2 diabetes—according to the study titled “Dramatic Drop in Ketoacidosis Rate after FreeStyle Libre System Initiation in Type 1 and Type 2 Diabetes in France, Especially in People with Low Self-Monitoring of Blood Glucose (SMBG): A Nationwide Study,” presented today at the American

Data Shows Potential Breakthrough Treatment Option for Glucose Management in Adolescents with Uncontrolled Diabetes Findings from an international study show a once-weekly injection of dulaglutide was superior in improving glycemic control in youth with type 2 diabetes compared to placebo. The trial was presented at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA) in New Orleans, LA, and simultaneously published in The New England Journal of Medicine . The findings come at a time when cases of type 2 diabetes among youth have more than doubled, since the pandemic

Study presented at ADA’s Scientific Sessions compared insulin-only mode of iLet to usual care The iLet bionic pancreas (BP)¹ significantly increased the percentage of time adults with type 1 diabetes (T1D) had glucose levels between 70–180 mg/dl, when compared to usual care (UC) therapy of either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), according to the study, “First Human Study Testing the iLet, a Purpose-Built Bionic Pancreas Platform,” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone